Danaher (DHR) Stock Movement Summary Danaher stock declined 6.58% as a post-earnings selloff extended into its second day, despite beating fourth-quarter expectations. Financial Results: - Q4 2025 adjusted EPS: $2.23 (beat estimate of $2.14) - Q4 2025 revenue: $6.84 billion (beat estimate of $6.79 billion) - Revenue increased 4.5% year-over-year with 2.5% non-GAAP core revenue growth - Biotechnology segment grew 9%; Life Sciences grew 2.5% 2026 Guidance: - Forecasted 3%-6% core revenue growth - Adjusted diluted EPS guidance: $8.35-$8.50 - Annual profit forecast in line with Wall Street estimates Analyst Actions: - KeyBanc reiterated Overweight rating with $310 price target - Evercore ISI raised price target to $254 from $250, maintaining Outperform rating Despite strong earnings and positive analyst ratings
Read full analysisDanaher (DHR) Stock Movement Summary Danaher stock declined 6.58% as a post-earnings selloff extended into its second day, despite beating fourth-quarter expectations. Financial Results: - Q4 2025 adjusted EPS: $2.23 (beat estimate of $2.14) - Q4 2025 revenue: $6.84 billion (beat estimate of $6.79 billion) - Revenue increased 4.5% year-over-year with 2.5% non-GAAP core revenue growth - Biotechnology segment grew 9%; Life Sciences grew 2.5% 2026 Guidance: - Forecasted 3%-6% core revenue growth - Adjusted diluted EPS guidance: $8.35-$8.50 - Annual profit forecast in line with Wall Street estimates Analyst Actions: - KeyBanc reiterated Overweight rating with $310 price target - Evercore ISI raised price target to $254 from $250, maintaining Outperform rating Despite strong earnings and positive analyst ratings
Danaher Corporation (DHR) is a publicly traded company in the Healthcare sector.